2024-513396-41-00招募中3 期
CARFILZOMIB - LENALIDOMIDE - DEXAMETHASONE (KRd) versus LENALIDOMIDE - DEXAMETHASONE (Rd) IN NEWLY DIAGNOSED MYELOMA PATIENTS NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: A RANDOMIZED PHASE III TRIAL (EMN20)
Fondazione European Myeloma Network Italy O.N.L.U.S.21 个研究点 分布在 1 个国家目标入组 340 人开始时间: 2024年8月12日最近更新:
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 340
- 试验地点
- 21
- 主要终点
- MRD evaluation will be performed on bone marrow samples obtained after 1 and 2 years of treatment in patients who achieved at least a VGPR during the first year of study treatment. The rate of MRD negativity is determined as the patients with MRD negativity at 2 years of treatment. For patients who withdraw or are lost to follow up before two years of treatment, the best MRD assessment will be considered.
研究概览
简要总结
The primary objective is to determine the efficacy, in term of minimal residual disease (MRD) negativity (MRD after 2 years of treatment), of the addition of Carfilzomib to the Lenalidomide-Dexamethasone drug association in newly diagnosed MM patients not eligible for autologous stem cell transplantation (ASCT); To determine the PFS of both treatment arms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Newly diagnosed symptomatic MM based on either standard CRAB criteria (at least 10% of bone marrow plasma cells plus CRAB defined as the onset of any of the following clinical symptoms: hypercalcemia, renal failure, anemia and bone lesions) or at least 10% of bone marrow plasma cells plus the presence of at least one of the following biomarkers of malignancy: 60% or greater clonal plasma cells on bone marrow examination; Serum involved/uninvolved free light chain (FLC) ratio of 100 or greater; More than one focal lesion on magnetic resonance imaging (MRI) that is at least 5 mm or greater in size.
- •LVEF (left ventricular ejection fraction) ≥ 40%: 2-D transthoracic echocardiogram (ECHO) is the preferred method of evaluation; multigated Acquisition Scan (MUGA) is acceptable if ECHO is not available
- •Pre-treatment blood pressure value < 140/90 mmHg even with adequate therapy: 24 hours blood pressure monitoring is the preferred method of evaluation; blood pressure diary at home for 2 weeks is acceptable.
- •Females of childbearing potential (FBCP) comply with the conditions of the Pregnancy Prevention Plan, including confirmation that she has an adequate level of understanding
- •FBCP must follow the Pregnancy Prevention Plan and use a highly effective and an additional barrier contraception method simultaneously for 4 weeks before starting therapy, during treatment and dose interruptions and for at least 30 days after the last dose of study drugs.
- •Males must use an effective barrier method of contraception if sexually active with FCBP during the treatment and for at least 90 days after the last administration of study drug/s. Male subjects must agree to refrain from sperm donation for at least 90 days after the last dose of carfilzomib.
- •Patient not eligible for ASCT (age ≥ 65 years or abnormal cardiac, pulmonary and liver function).
- •Patient defined as fit or intermediate according to the IMWG (International Myeloma Working Group) frailty score.
- •Patient has given voluntary written informed consent.
- •Patient is able to be compliant with hospital visits and procedures required per protocol.
- •Patient agrees to use acceptable methods for contraception.
- •Patient has measurable disease according to IMWG criteria.
- •Patient has ECOG (Eastern Cooperative Oncology Group) performance status <
- •Pre-treatment clinical laboratory values within 30 days before randomization: Platelet count ≥50 x 10^9/L (≥30 x 10^9 /L if myeloma involvement in the bone marrow is > 50%), Absolute neutrophil count (ANC) ≥ 1 x 10^9/L without the use of growth factors, Corrected serum calcium ≤14 mg/dL (3.5 mmol/L), Alanine transaminase (ALT): ≤ 3 x the ULN, Total bilirubin: ≤ 2 x the UL, Calculated or measured creatinine clearance: ≥ 30 mL/minute.
排除标准
- •Serious medical condition, laboratory abnormality or psychiatric illness that prevented the subject from the screening or place the subject at unacceptable risk.
- •Presence of peripheral neuropathy or neuropathic pain grade 2 or higher, as defined by National Cancer Institute Common Toxicity Criteria (NCI CTC) 5.
- •Presence of incontrolled hypertension defined as persistent hypertension (>140/90 mmHg) regardless treatment with 3 drugs, including a diuretic.
- •Contraindication to any of the required drugs or supportive treatments and hypersensitivity to any excipient of the study drugs.
- •Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib).
- •Invasive malignancy within the past 3 years.
- •Administration of any experimental drug within 4 weeks prior to the baseline or within 5 drug half-lives.
- •Patient defined as frail according to the IMWG frailty score (pts with age >80 years old).
- •Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid < to the equivalent of dexamethasone 40 mg/day for 4 days)
- •Pregnant or lactating females.
- •Presence of clinical active infectious hepatitis type A, B, C or HIV.
- •Presence of acute active infection requiring antibiotics or infiltrative pulmonary disease.
- •Presence of pulmonary hypertension and interstitial lung disease.
- •Presence of uncontrolled arrhythmias or history of QT prolongation.
- •Presence of myocardial infarction or unstable angina ≤ 6 months or other clinically significant heart disease.
结局指标
主要结局
MRD evaluation will be performed on bone marrow samples obtained after 1 and 2 years of treatment in patients who achieved at least a VGPR during the first year of study treatment. The rate of MRD negativity is determined as the patients with MRD negativity at 2 years of treatment. For patients who withdraw or are lost to follow up before two years of treatment, the best MRD assessment will be considered.
MRD evaluation will be performed on bone marrow samples obtained after 1 and 2 years of treatment in patients who achieved at least a VGPR during the first year of study treatment. The rate of MRD negativity is determined as the patients with MRD negativity at 2 years of treatment. For patients who withdraw or are lost to follow up before two years of treatment, the best MRD assessment will be considered.
PFS will be measured from the date of randomization to the date of first observation of PD, or death from any cause as an event. Subjects who withdraw from the study will be censored at the time of the last complete disease assessment. Subjects who complete the study, have not progressed, and are still alive at the cut-off date of final analysis will be censored at the cut-off date. All subjects who were lost to FU will also be censored at the time of last contact.
PFS will be measured from the date of randomization to the date of first observation of PD, or death from any cause as an event. Subjects who withdraw from the study will be censored at the time of the last complete disease assessment. Subjects who complete the study, have not progressed, and are still alive at the cut-off date of final analysis will be censored at the cut-off date. All subjects who were lost to FU will also be censored at the time of last contact.
次要结局
- Response rate (sCR, CR, VGPR, PR) of experimental KRd regimen vs Rd regimen.
- PFS2 will be measured from the date of first randomization to the date of observation of second disease progression or death to any cause as an event. In case of date of second progression is not available, date of start of third line treatment can be used. Subjects who withdraw from the study will be considered at the time of the last complete disease assessment. Subjects who complete the study or were lost to follow-up, have no progressed, and are still alive at final analysis will be censored
- TTP will be measured from the date of randomization to the date of first observation of PD, or deaths related to PD. Subjects who withdraw from the study or die from causes other than PD will be censored at the time of the last complete disease assessment. Subjects who complete the study, have not progressed, and are still alive at the cut-off date of final analysis will be censored at the cut-off date. Subjects lost to FU will also be censored at the time of last contact.
- DOR is defined as time between first documentation of response and PD. Responders without disease progression will be censored either at the time of lost to FU, at the time of death due to other cause than PD, or at the end of the study.
- OS is defined as the time between randomization and death. Subjects who die will be censored at time of death as an event, regardless cause of death. Subjects who withdraw consent will be censored at the time of withdrawal. Subjects who complete the study and are still alive at the cut-off date of final analysis will be censored at the cut-off date. Subjects lost to FU will also be censored at the time of last contact.
- TNT will be measured from the date of randomization to the date of next anti-myeloma therapy. Death due to any cause before starting therapy will be considered an event. Subjects who withdraw from the study will be censored at the time of the last complete disease assessment. Subjects who complete the study, have not progressed, and are still alive at the cut-off date of final analysis will be censored at the cut-off date. Subjects lost to FU will also be censored at the time of last contact.
- Toxicity
- Quality of life defined by EOCTC QLQ-C30 and QLQ-MY20.
- To determine the incidence of dose reduction and drug discontinuation in both treatment arms.
- To determine the benefit of proper cardiovascular baseline assessment and monitoring in both treatment arms: to mitigate major cardiovascular adverse event incidence, to prolong duration of treatment, to improve efficacy.
- To determine the impact of MRD negativity on PFS, PFS2, TTP, TNT and OS.
- To determine difference of response and outcome (PFS, PFS2, TTP, TNT and OS) in subgroups analysis with different prognostic factors.
研究者
Sara Bringhen
Scientific
Fondazione European Myeloma Network Italy O.N.L.U.S.
研究点 (21)
Loading locations...
相似试验
进行中（未招募）
1 期
A randomized trial that compares Carfilzomib - Lenalidomide - Dexamethasone (KRd) versus Lenalidomide - Dexamethasone (Rd) in new diagnosed myeloma patients not elegible for trasplant.PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR NOT ELIGIBLE TO ASCTMedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104CTIS2024-513396-41-00Fondazione European Myeloma Network Italy O.N.L.U.S.340
进行中（未招募）
1 期
Carfilzomib + Lenalidomide +Dexamethasone for BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomasBTK inhibitors relapsed-refractory or intolerant mantle cell lymphomasMedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000540-25-ITFONDAZIONE ITALIANA LINFOMI ONLUS59
进行中（未招募）
1 期
Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple MyelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000054086EUCTR2016-005008-24-ESFUNDACIÓN PETHEMA270
进行中（未招募）
1 期
se of a novel chemotherapeutic regimen in an attempt to eradicate residual myeloma disease after a first autologous stem cell Transplantation.MedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2016-004778-16-ATDepartment of Medicine I, Ordensklinikum Linz, Elisabethinen Hospital Linz41
进行中（未招募）
3 期
A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for TransplantNew Diagnosis TumorMultiple MyelomaNCT04096066Fondazione EMN Italy Onlus84